Project Grant R00HL159258

Award Date 7/22/24
Completion Date 6/30/27
Dollars Obligated $1.3M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $656,988 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study the role of HMGB1 in the lung's response to bacterial injury. The objective is to develop a therapeutic strategy to replace a failed component of the macrophage lung injury response and enable healing in patients with...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996 to the University of Southern California (USC) from April 1, 2025 to January 31, 2029. The funding supports research to investigate the role of the protein PDLIM2 in regulating alveolar macrophage function, which is critical for lung innate immunity, inflammation, and respiratory diseases. The research aims to elucidate the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how tissue factors in the lung alter the inflammatory response to viral infections, leading to the loss of alveolar type 2...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $139,088 to the Icahn School of Medicine at Mount Sinai to conduct research on the role of specialized pro-resolving mediators (SPMs) in resolving inflammation and their association with respiratory outcomes in individuals with emphysema. The project aims to characterize circulating SPM concentrations as a biomarker for...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program, provides $430,760 to the University of Pittsburgh to conduct research on improving host defense against the deadly Gram-negative bacterium, Pseudomonas aeruginosa. The key objectives are to: 1) Determine the role of the CXCR4 chemokine receptor and galectin-3 protein in the protective function of lung...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,831,848 to the University of Rochester to investigate how neonatal microbiome colonization impacts lung immunity and regeneration. The research aims to elucidate how early-life microbial dysbiosis remodels the developmental program in lung-resident lymphocytes and epithelial cells, contributing to chronic respiratory disease. Key...
This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...
The University of Tennessee Health Science Center received a $615,455 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award, effective September 1, 2024 through June 30, 2028, supports research to investigate the role of eosinophils in promoting antibacterial immunity against Streptococcus pneumoniae, a leading cause of bacterial pneumonia that often co-occurs with influenza infections. The...
This three-year, $2.97 million Project Grant from the National Institutes of Health's Trans-NIH Research Support program will support the development of a novel lung research platform to probe pulmonary (patho)physiology in real-time at the cellular level. Trustees of Boston University will receive funding to create the LungEx platform, which includes long-term ex vivo maintenance of mouse and human lungs under near-physiological conditions. A key innovation is a "Crystal" ribcage that...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,063,324 to Tulane University to conduct research on CD4+ T cell immunity in the respiratory tract. The research aims to shed new light on pulmonary host defenses that can be leveraged to reduce the global burden of pneumonia mortality and morbidity. Specifically, the project will use murine and primate respiratory tract samples to...

ESTABLISHING MECHANISMS OF LOX-1-DEPENDENT IMMUNE REGULATION DURING PNEUMONIA - ABSTRACT PNEUMONIA IS THE LEADING CAUSE OF INFECTION-RELATED DEATHS WORLDWIDE, A FACT THAT IS SET TO RISE EXPONENTIALLY WITH THE SARS-COV2 PANDEMIC. RECOVERY FROM PNEUMONIA REQUIRES BOTH CLEARANCE OF THE PATHOGEN AND RESOLUTION OF INFECTION, THE LATTER OF WHICH IS CRITICAL TO RESUME NORMAL LUNG FUNCTION. WHILE BOTH PROCESSES ARE IMPORTANT TO HOST HEALTH, THERE IS VASTLY LESS KNOWN ABOUT THE MECHANISMS THAT REGULATE RESISTANCE TO AND RESOLUTION OF TISSUE INJURY DURING PNEUMONIA, REPRESENTING A LARGE KNOWLEDGE GAP IN OUR UNDERSTANDING OF THE BIOLOGY OF THE LUNG AND ITS REPAIR PROCESSES. HERE, WE PROPOSE THAT LECTIN-LIKE OXIDIZED LOW-DENSITY LIPOPROTEIN RECEPTOR-1 (LOX-1) MODULATES ACUTE PULMONARY INFLAMMATION IN WAY THAT PROMOTES RESOLUTION THROUGH REPROGRAMMING OF LEUKOCYTE RESPONSE. LOX-1 IS A CLASS E SCAVENGER RECEPTOR, PRIMARILY KNOWN FOR ITS ROLE IN PROMOTING VASCULAR INFLAMMATION DURING ATHEROSCLEROSIS. IN DIRECT CONTRAST, OUR DATA SUGGESTS THAT LOX-1 HAS A UNIQUE FUNCTION IN THE LUNG, WHERE IT PREVENTS EDEMATOUS LUNG INJURY AND INFLAMMATION, INDEPENDENT OF BACTERIAL CLEARANCE IN MURINE MODELS OF ESCHERICHIA COLI AND STREPTOCOCCUS PNEUMONIAE PNEUMONIA. MOREOVER, LOX-1 AND ITS MAJOR LIGAND OXIDIZED LOW-DENSITY LIPOPROTEIN (OXLDL) ARE ELEVATED IN PATIENTS WITH ARDS AS A RESULT OF A CONFIRMED DIAGNOSIS OF PNEUMONIA. ANALYSIS OF THE CELLULAR EXPRESSION OF LOX-1 IN THE LUNG REVEALED THAT ALVEOLAR MACROPHAGES AND RECRUITED (AIRSPACE) NEUTROPHILS ARE UNIQUELY ENRICHED FOR LOX-1 EXPRESSION. HEMATOPOIETIC CELLS ARE ALSO LIKELY SOURCES OF LOX-1-DEPENDENT PROTECTION, AS LOX-1-/- (WT RECIPIENT) CHIMERAS ARE SIGNIFICANTLY MORE PROTECTED FROM INJURY THAN WT (LOX-1-/- RECIPIENT) CHIMERAS DURING PNEUMONIA. ASSESSMENT OF THE SPECIFIC EFFECTS OF LOX-1 INHIBITION ON ALVEOLAR MACROPHAGES DEMONSTRATED THAT WITH INHIBITION MACROPHAGES ARE SKEWED TOWARDS INFLAMMATION AND EXHIBIT METABOLIC CHANGES ASSOCIATED WITH INCREASED GLYCOLYSIS AND LOWER FATTY ACID OXIDATION CONSISTENT WITH INFLAMMATORY MACROPHAGES. MOREOVER, WE DISCOVERED THAT RECRUITED NEUTROPHILS DIFFER IN THEIR EXPRESSION OF LOX-1, WHERE ABOUT HALF OF NEUTROPHILS ARE POSITIVE DURING INFECTION. CURIOUSLY, WE ALSO FOUND PHENOTYPIC DIFFERENCES ASSOCIATED WITH LOX-1+ NEUTROPHILS THAT SUGGEST INCREASED CHOLESTEROL METABOLISM, WHICH MAY UNIQUELY PROMOTE TISSUE RESOLUTION. TAKEN TOGETHER, LEUKOCYTES ARE AN IMPORTANT SOURCE OF LOX-1 AND ARE LIKELY RESPONSIBLE FOR LOX-1-DEPENDENT PROTECTION DURING PNEUMONIA. HOWEVER, WHETHER AND HOW LOX-1 ELICITS ITS PROTECTIVE EFFECTS ON LEUKOCYTES IS NOT KNOWN. THUS, WE PROPOSE A CENTRAL HYPOTHESIS THAT LOX-1 SIGNALING EVOKES TISSUE-PROTECTIVE MECHANISMS IN LEUKOCYTES (K99), THAT ARE ASSOCIATED WITH METABOLIC CHANGES CONSISTENT WITH REDUCED INFLAMMATION AND INCREASED TISSUE RECOVERY (R00). RESULTS FROM OUR INVESTIGATIONS WILL BE THE FIRST TO ELUCIDATE HOW LOX-1 IS REGULATED AT THE TRANSCRIPTIONAL AND METABOLIC LEVEL IN THE UNIQUE MICROENVIRONMENT OF THE LUNG, WHERE IT LIKELY FACILITATES RECOVERY FROM PNEUMONIA AND LUNG HOMEOSTASIS.

Posted 7/17/24